UK Buyers Club Aims For Lower-Cost Cystic Fibrosis Drugs
Executive Summary
A buyers club in the UK is planning to import generic versions of Vertex’s cystic fibrosis drugs that are not available on the NHS. Some commentators think such clubs may become more common.
You may also be interested in...
More Drug Price Disclosure In Store As WHO Delegates Pass Landmark Resolution
Many see the World Health Assembly resolution on drug pricing transparency as a game changer and welcome the fact that it will shine light on an area that critics says is far too opaque. Some are unhappy that the final version is not as strong as the original draft, but industry will be relieved the WHA ultimately did not adopt a requirement for mandatory disclosure of R&D costs.
NHS England Offers ‘Improved’ Orkambi Deal, But Vertex Lukewarm
The NHS in England says it has made a “revised and improved” offer to Vertex to make Orkambi available, but the company is not impressed and says its attitude to the negotiations has been mischaracterized.
Industry Calls For Canadian Pricing Guideline Consultation To Be Suspended
IMC, the R&D-based pharmaceutical industry association in Canada, says the guideline will “exacerbate an already unpredictable regulatory environment.”